Principal Investigator
Enrollment Status
Clinical Trial ID
Clinical Trial Summary
The objective of this study is to collect long-term safety information (i.e., for 5 years
after treatment) associated with voretigene neparvovec-rzyl (vector and/or transgene), its
subretinal injection procedure, the concomitant use of corticosteroids, or a combination of
these procedures and products.
The enrollment period will last for two years from the first treatment following product
approval (through 31March2020) and include a minimum of 40 patients.
Phase
Other
Funding Agency/Sponsor
Industry
Disease
Neuro-Ophthalmology
Enrollment Eligibility
Inclusion Criteria:
1. Received voretigene neparvovec-rzyl in at least one eye.
2. Signed informed consent/assent (when applicable). These are obtained as required under
institutional policies and applicable laws and regulations unless a consent waiver is
obtained from the Institutional Review Board (IRB)/Independent Ethics Committee (IEC).
Exclusion Criteria:
1. Previously participated in, or are currently participating in, a Spark Therapeutics
clinical trial and received voretigene neparvovec-rzyl in both eyes.